tirzepatide who makes Retatrutide for weight loss: Study shows 30% body weight loss Tirzepatide, a New Era of

For oral GLP-1 medications approved by the U.S

Patients report symptoms such as severe and prolonged vomiting, nausea, abdominal pain, and malnutrition

GLP-1 drugs appear to have direct protective effects on the cardiovascular system, reducing inflammation, improving endothelial function, and potentially stabilizing atherosclerotic plaques

Pericardial effusion, pedal edema, and tachycardia are potential concerns at higher doses, which is why cardiac monitoring is recommended

Female GLP-1RA users showed increased HSV risk (HR = 1.51), and poorly controlled patients (HbA1c 7%) had higher HSV risks (HR = 1.195)